Heterogeneity of curcumin studies: a review of 103 randomized trials

The most immediate result is that having many studies does not equate to having a single answer. Twenty-three of the 42 outcomes reached statistical significance. This indicates that, for those indicators, the difference observed between the intervention and the placebo was unlikely to be attributable to chance alone according to the statistical criteria adopted. However, it does not automatically indicate a significant change for the health of every single person.

The authors assigned a high level of evidence to glycemia, C-reactive protein, HDL cholesterol, and body weight. Glycemia measures blood glucose after a period without food; HDL cholesterol is a fraction of cholesterol involved in lipid transport. For waist circumference, body mass index, insulin, and HOMA-IR—an indirect estimate of insulin resistance—the reliability of the results is moderate. Fourteen outcomes had low evidence, and another fourteen had very low evidence. Jafari and colleagues therefore report possible changes in glycemic, lipid, inflammatory, and oxidative parameters, but they do not demonstrate a uniform effect, nor do they prove the prevention or cure of diseases.

This publication is particularly useful for correctly interpreting expressions such as "clinically studied turmeric." By bringing together many trials, it shows that human literature exists and that some signals are converging. At the same time, it makes it clear how different the objectives are: a blood value, a body measurement, or a marker of inflammation are not the same thing as an improvement in symptoms, quality of life, or long-term disease risk.

Practical relevance also concerns product composition. An extract, a formulation with higher absorption, and the spice added to meals are not automatically equivalent in terms of the amount ingested, availability in the body, and context of use. An independent review of body measurements observed small average effects and noted differences based on the formulation, with many studies at high risk of bias [1]. Another synthesis of reviews found favorable results for some inflammatory and vascular markers, but not for all the indicators examined [2]. These verifications support the general picture without turning it into a guarantee for every product.

The main limitation is heterogeneity, meaning the presence of significant differences between studies: participants with different conditions, non-comparable preparations, varying durations, and outcomes measured using different methods. An average value obtained from aggregation can be informative, but it does not allow us to determine which dose, form, or duration is suitable for everyone. Furthermore, the review reports that the methodological quality of the included studies requires caution and calls for larger, longer-term trials.

The work does not demonstrate that curcumin used in cooking has the same effects as the capsules evaluated in the trials. It does not prove that a change in a biomarker prevents a disease or replaces medical treatments. It also does not allow for the deduction of an individual effect: in a small crossover trial on 18 healthy smokers, an acute dose of 5 g did not modify vascular function in the entire group, while some subgroup analyses suggested different responses [3]. Individual variability is therefore a possible explanation, not proof that a formulation works selectively based on sex or cardiovascular risk.

The first confirmation concerns the fact that average results, when present, can be small and depend on the form of the product. An umbrella review with an updated meta-analysis brought together 50 randomized trials on body measurements. It found average reductions in body mass index, weight, and waist circumference; for weight, the mean difference was −0.59 kg, with a 95% confidence interval from −0.81 to −0.36. However, the authors classified 21 trials as being at high risk of bias and observed differences linked to formulations with increased bioavailability, i.e., designed to improve the absorbed portion [1]. This directly supports the idea that the quantity of studies does not make all preparations equivalent; the confirmation is moderate for the topic of body measurements, but it does not extend to every outcome of the Jafari review.

A second point concerns biological markers. A meta-analysis of meta-analyses, based on 21 trial syntheses, found average reductions in C-reactive protein, tumor necrosis factor-alpha, and interleukin-6, along with changes in certain oxidative indicators and endothelial function [2]. Endothelial function describes the ability of the inner lining of blood vessels to regulate blood flow. The link with Jafari and colleagues is direct for inflammatory and oxidative markers; however, it remains indirect with respect to clinical outcomes, because biomarkers are not synonymous with disease prevention.

Finally, a placebo-controlled trial in 90 adults between 50 and 69 years of age who were overweight evaluated an extract composed of an aqueous fraction and a fraction extracted with supercritical carbon dioxide for 12 weeks. Compared to the placebo, the treated group showed lower values of C-reactive protein and complement C3, in addition to differences in weight and body mass index [4]. Complement C3 is a protein involved in immune defenses and inflammation. This human result is consistent with some aggregated signals, but it concerns a specific extract, a limited sample, and researchers employed by the manufacturing company; the confirmation is therefore limited.

Contradictory evidence does not negate the average findings of the review, but it does show why they should not be generalized. In a crossover trial by Barber-Chamoux and colleagues, 18 healthy smokers received a single 5 g dose of curcumin or a placebo. After two hours, no significant effect on flow-mediated dilation was observed in the group as a whole; flow-mediated dilation is a test that assesses how an artery responds to increased blood flow. Exploratory analyses suggested differences based on sex and cardiovascular risk, but the very small sample size and short observation period severely limit these conclusions [3]. The study therefore contradicts the idea of a predictable and uniform vascular response.

A second randomized trial followed 39 healthy middle-aged or older adults for 12 weeks. The Longvida formulation provided approximately 400 mg of curcumin per day within 2,000 mg of the product. No improvements compared to the placebo were found in the main measures of strength, mobility, balance, endurance, or cognitive function; the P-values for these comparisons were greater than 0.05 [5]. This evidence does not directly conflict with the blood markers in the Jafari review, as it measures different outcomes. However, it is relevant because it serves as a reminder that a change in certain biological indicators does not necessarily lead to a perceptible functional improvement in healthy individuals.

No directly conflicting evidence sufficiently relevant to every single outcome of the review was identified; this does not prove the absence of contrary results.